Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Acrivon Therapeutics, Inc. | Chief Development Officer | Common Stock | 17K | $134K | $7.92 | Nov 14, 2024 | Direct |
Acrivon Therapeutics, Inc. | Chief Development Officer | Stock Option (Right to Buy) | 45K | Mar 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2024 | 1 | -$3.18K | 4 | Nov 18, 2024 | Chief Development Officer |
ACRV | Acrivon Therapeutics, Inc. | Aug 14, 2024 | 1 | -$2.82K | 4 | Aug 16, 2024 | Chief Development Officer |
ACRV | Acrivon Therapeutics, Inc. | May 14, 2024 | 1 | -$3.36K | 4 | May 16, 2024 | Chief Development Officer |
ACRV | Acrivon Therapeutics, Inc. | Mar 1, 2024 | 1 | $0 | 4 | Nov 27, 2024 | Chief Development Officer |
ACRV | Acrivon Therapeutics, Inc. | Feb 14, 2024 | 1 | -$1.59K | 4 | Feb 16, 2024 | Chief Development Officer |
ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2023 | 1 | -$7.09K | 4 | Nov 16, 2023 | Chief Medical Officer |
ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2022 | 2 | $0 | 4 | Nov 16, 2022 | Chief Medical Officer |
ACRV | Acrivon Therapeutics, Inc. | Nov 9, 2022 | 0 | $0 | 3 | Nov 9, 2022 | Chief Medical Officer |